Concizumab

Medication

Routes of
administrationSubcutaneousDrug classAntihemorrhagicATC code
  • B02BX10 (WHO)
Legal statusLegal status
IdentifiersCAS Number
  • 1312299-39-0
DrugBank
  • DB12820
UNII
  • 68603V9EAF
KEGG
  • D11847
Chemical and physical dataFormulaC6462H10004N1712O2046S46Molar mass145887.81 g·mol−1

Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.[5] It is an anti-tissue factor pathway inhibitor.[5]

Concizumab was approved for medical use in Canada in March 2023.[4][7]

Medical uses

Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[5][6]

Society and culture

Names

Concizumab is the international nonproprietary name.[8]

References

  1. ^ a b "Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.
  2. ^ "Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.
  3. ^ "AusPAR: Alhemo". Therapeutic Goods Administration (TGA). 18 March 2024. Retrieved 31 March 2024.
  4. ^ a b "Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.
  5. ^ a b c d "Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.
  6. ^ a b "Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.
  7. ^ "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Archived from the original on 9 June 2023. Retrieved 9 June 2023 – via Newswire.
  8. ^ World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
  • v
  • t
  • e
Antihemorrhagics
(coagulation)
Systemic
Vitamin K
  • Phytomenadione (K1)
  • Menadione (K3)
Coagulation
factors
Other
systemic
Local
Antifibrinolytics
Portal:
  • icon Medicine


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e